Precigen (STU:I5X) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:I5X Precigen Inc STU:I5X
56 GF Score
Price €6.20
GF Value €13.14
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Precigen FFO per Share?

FFO per Share only applies to REITs.

STU:I5X
56GF Score
Precigen Inc STU:I5X
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €6.20 is trading 52.8% below its estimated GF Value™ of €13.14. GuruFocus considers Precigen to be Possible Value Trap.

Key valuation signals for STU:I5X:

  • FFO per Share:
  • GF Value™: €13.14 vs. price of €6.20 (52.8% below fair value)
  • GF Score™: 56/100 with 9 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
56GF Score

Get the complete analysis for STU:I5X

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.20
Price
€13.14
GF Value